Treatment
Car-t clinical trials
We’re tracking 421 recruiting studies that include Car-t, each written for real people, not researchers, below.
Recruiting studies
- NCT06916767RecruitingPhase 1
Study of BAFF CAR-T cells for CLL or SLL
This trial tests a new type of immune cell therapy (BAFF CAR-T cells) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded after at least two prior treatments, including a BTK inhibitor and a BCL2 inhibitor. The goal is to see if these engineered cells can fight the cancer.
Cleveland, OhioAges 18 years+ - NCT06658951Recruiting
HER2-targeted CAR-T cell therapy for advanced solid tumors
This trial tests a new type of immunotherapy called CAR-T cells that are designed to attack cancer cells that have a high amount of a protein called HER2. It is for people with advanced solid tumors (like certain breast, stomach, or lung cancers) that have not responded to standard treatments.
Zhengzhou, HenanAges 18–70 - NCT06481735RecruitingPhase 1/Phase 2
Modified donor CAR-T for B-cell leukemia
This trial tests a new type of CAR-T cell therapy for people with B-cell acute lymphoblastic leukemia that has returned or not responded to standard treatment. The CAR-T cells are made from a donor and modified to target the CD19 protein on leukemia cells.
Beijing, Beijing MunicipalityAges 16–70 - NCT05659628RecruitingPhase 1
CD19 CAR-T plus PD-1 antibody for relapsed lymphoma
This Phase 1 study tests a new type of immune cell therapy (CD19 CAR-T) combined with an anti–PD-1 drug for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It aims to improve cancer control when standard treatments have not worked or the cancer has come back.
Hangzhou, ZhejiangAges 18–75 - NCT06125652RecruitingPhase 1/Phase 2
Anti-Tim-3/CD123 CAR T-cell therapy for resistant AML
This study tests a special immune cell therapy (CAR T-cells) that targets two proteins on leukemia cells. It is for people whose AML has returned or not responded to standard treatments.
Xuzhou, JiangsuAges 18–70 - NCT06428188RecruitingPhase 1/Phase 2
CAR-T cells targeting BCMA/CD19 for autoimmune diseases
This trial tests a new treatment called CAR-T cells that target two proteins (BCMA and CD19) on immune cells. It is for people with certain autoimmune diseases that have not improved with standard treatments.
Beijing, Beijing MunicipalityAges 21–90 - NCT07179692RecruitingPhase 1
CEA-targeted CAR-T therapy for advanced solid tumors
This trial tests a type of immunotherapy called CAR-T, which is designed to recognize and attack cancer cells that have a protein called CEA on their surface. It's for people with advanced cancers like colorectal, esophageal, gastric, pancreatic, lung, or bile duct cancer who have tried at least two standard treatments.
Hefei, AnhuiAges 18 years+ - NCT07148791RecruitingPhase 2
CAR-T therapy for relapsed or refractory IgG4-related disease
This trial tests whether a special type of immune cell therapy (CAR-T) can help people whose IgG4-related disease persists despite steroids or rituximab. It focuses on those with inflammation in two or more major organs.
Beijing, Beijing MunicipalityAges 18–75 - NCT07106684RecruitingPhase 2
Stem cell transplant with car-t and bi-specific antibody for plasma cell leukemia
This trial tests a treatment plan for newly diagnosed plasma cell leukemia that involves a stem cell transplant followed by two types of immunotherapy: CAR-T cells targeting BCMA and a bi-specific antibody targeting GPRC5D. The goal is to see if this approach can help keep the cancer in remission.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07032129RecruitingPhase 1/Phase 2
Targeted cell therapy for multiple myeloma that returned or didn't respond
This trial tests a new type of treatment using your own immune cells (called CAR-T cells) that target two proteins on myeloma cells: BCMA and GPRC5D. It's for people whose myeloma has come back or stopped responding to standard treatments, and who may have few other options left.
Beijing, Beijing MunicipalityAges 21–90 - NCT05518253RecruitingPhase 1
CAR-T treatment for CD70-positive advanced solid tumors
This trial tests a lab-made immune therapy (CAR-T) that targets a protein called CD70 found on some advanced cancers. It’s designed for people whose solid tumors have spread and no standard treatments have worked or weren’t tolerated.
Hangzhou, ZhejiangAges 18 years+ - NCT07368270RecruitingPhase 1
Anti-PD1 armored CAR-T cells for adults with relapsed/refractory DLBCL
This trial tests a new kind of cell therapy that combines CAR-T cells (which find and kill cancer cells) with an anti-PD1 'armor' to boost their power. It is for adults with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to earlier treatments.
SuzhouAges 18 years+ - NCT07106710RecruitingPhase 2
Stem cell transplant plus two targeted therapies for ultra-high-risk myeloma
This trial tests a stem cell transplant followed by two targeted therapies — a BCMA CAR-T and a GPRC5D/CD3 bispecific antibody — to treat newly diagnosed multiple myeloma that has ultra-high-risk features. The goal is to see if this combination can better control the disease.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT04532281RecruitingEarly Phase 1
CD19 CAR-T therapy for relapsed or resistant blood cancers
This early-phase study tests a treatment called CD19 CAR-T, made from your immune cells, for people whose CD19+ blood cancer has come back or did not respond. It may help your body better recognize and attack cancer cells, but eligibility is tight and the study is still early.
Hangzhou, ZhejiangAges Any age - NCT06126406RecruitingPhase 1
CEA-targeting CAR-T cell therapy for advanced solid tumors
This trial tests a new immune cell therapy (CAR-T) designed to attack cancer cells that make a protein called CEA. It may be an option for people with advanced colorectal, esophageal, gastric, or pancreatic cancer who have already tried at least two standard treatments.
Wuhu, AnhuiAges 18 years+ - NCT07284433RecruitingPhase 1/Phase 2
Donor cell therapy for B-cell blood cancers
This trial tests a new treatment made from donor cells that target two proteins (CD19 and CD20) found on certain blood cancer cells. It may be an option for people whose B-cell lymphoma or chronic lymphocytic leukemia has come back or hasn't responded to at least two prior treatments.
Chicago, IllinoisAges 18 years+ - NCT06548607RecruitingEarly Phase 1
CAR-T therapy for autoimmune diseases
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
Bengbu, AnhuiAges 18–70 - NCT05341492RecruitingEarly Phase 1
CAR-T therapy for EGFR/B7H3-positive lung and triple-negative breast cancer
This early-phase trial tests CAR-T cells designed to find and attack tumors that show EGFR or B7H3 markers. It may help people with advanced lung cancer or triple-negative breast cancer after standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT07489989RecruitingPhase 2
Combination therapy to boost CAR-T for B-cell lymphoma
This trial tests a new combination of drugs to make CAR-T cell therapy work better for people with certain types of B-cell lymphoma. It adds the drugs chidamide and a PD-1 inhibitor to the usual CAR-T treatment, aiming to improve response.
Beijing, Beijing MunicipalityAges 18–85 - NCT06179524RecruitingPhase 2
CAR-T-19 for CD19-positive B-ALL in children and young adults
This trial tests a new type of immunotherapy called CAR-T-19 for children and young adults up to age 25 whose B-ALL has returned or is not responding to standard treatments. The CAR-T cells are engineered to find and destroy leukemia cells that have the CD19 protein.
TianjinAges Up to 25 years - NCT07072494RecruitingPhase 1/Phase 2
CD19 CAR-T cells as consolidation for B-cell ALL
This trial tests a single infusion of CD19 CAR-T cells as a consolidation treatment to keep leukemia in remission for patients who are not eligible for or decline a stem cell transplant. The goal is to see if this therapy can prevent relapse.
Guangzhou, GuangdongAges 14–80 - NCT06043466RecruitingPhase 1
CAR-T cell therapy for CEA-positive advanced solid tumors
This trial tests a new cell therapy called CAR-T that targets cancer cells with a protein called CEA. It is for people with certain advanced cancers that have not responded to standard treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT06081478RecruitingPhase 2
Targeted CAR-T cell therapy for advanced lymphoma or leukemia
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
Beijing, Beijing MunicipalityAges 14–85 - NCT07575971RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for High-Risk B-Cell Acute Lymphoblastic Leukemia
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target leukemia cells after chemotherapy has put your disease into remission. The goal is to help prevent the leukemia from coming back, especially for patients at high risk of relapse.
Beijing, Beijing MunicipalityAges 18–85
Common questions
- Are there clinical trials studying Car-t?
- Yes. Clin2 currently lists 421 recruiting studies that include Car-t, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Car-t trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Car-t an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Car-t or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.